111627-29-3

Basic information

• Product Name: 4-[Bis(4-fluorophenyl)methylene]piperidinehydrobromide
• Synonyms: 4-[Bis(4-fluorophenyl)methylene]piperidinehydrobromide;4-[bis(4-fluorophenyl)methylidene]piperidine,hydrobromide
• CAS NO: 111627-29-3
• Molecular Formula: BrH*C₁₈H₁₇F₂N
• Molecular Weight: 366.26
• Mol File: 111627-29-3.mol

Chemical Properties

• Boiling Point: 435.9°C at 760 mmHg
• Flash Point: 217.4°C
• Appearance: /
• Vapor Pressure: 3.99E-08mmHg at 25°C
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 4-[Bis(4-fluorophenyl)methylene]piperidinehydrobromide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[Bis(4-fluorophenyl)methylene]piperidinehydrobromide(111627-29-3)
• EPA Substance Registry System: 4-[Bis(4-fluorophenyl)methylene]piperidinehydrobromide(111627-29-3)

Safety Data

• Hazardous Substances Data: 111627-29-3(Hazardous Substances Data)

Usage

Uses

Used in Neuroscience Research:
4-[Bis(4-fluorophenyl)methylene]piperidinehydrobromide is used as a selective dopamine D2-like receptor antagonist for studying the role of dopamine receptors in the central nervous system. Its potency and selectivity make it an invaluable tool in understanding the mechanisms underlying various neurological and psychiatric disorders.
Used in Pharmaceutical Development:
In the pharmaceutical industry, 4-[Bis(4-fluorophenyl)methylene]piperidinehydrobromide is utilized as a potential therapeutic agent for the treatment of conditions such as schizophrenia and substance abuse disorders. Its antagonistic action on dopamine D2 and D3 receptors has shown promise in preclinical studies, offering new avenues for the development of more effective treatments for these challenging conditions.
Used in Drug Discovery:
4-[Bis(4-fluorophenyl)methylene]piperidinehydrobromide serves as a lead compound in drug discovery efforts, providing a foundation for the design and synthesis of new molecules with improved pharmacological properties. Its unique structure and activity offer opportunities for the development of more selective and potent dopamine receptor antagonists, which could lead to better therapeutic options for patients suffering from neurological and psychiatric disorders.

InChI:InChI=1/C18H17F2N.BrH/c19-16-5-1-13(2-6-16)18(15-9-11-21-12-10-15)14-3-7-17(20)8-4-14;/h1-8,21H,9-12H2;1H

Upstream product

• 111627-27-1 α,α-bis(4-fluorophenyl)-1-(phenylsulfonyl)-4-piperidinemethanol 
• 1126-09-6 4-carbethoxypiperidine 
• 111627-26-0 1-(phenylsulfonyl)-4-piperidinecarboxylic acid ethyl ester 
• 108-95-2 phenol 

Downstream Products

• 58113-48-7 1-[4-[3-[4-[bis(4-fluorophenyl)methylene]-1-piperidinyl]propoxy]-3-methoxyphenyl]ethanone 

Relevant articles and documents

Synthesis, Calcium-Channel-Blocking Activity, and Antihypertensive Activity of 4-(Diarylmethyl)-1-piperidines and Structurally Related

A series of 4-(diarylmethyl)-1-piperidines and structurally related compounds were synthesized as calcium-channel blockers and antihypertensive agents.Compounds were evaluated for calcium-channel-blocking activity by determineng their ability to antagonize calcium-induced contractions of isolated rabbit aortic strips.The most potent compounds were those with fluoro substituents in the 3- and/or 4-positions of both rings of the diphenylmethyl group.Bis(4-fluorophenyl)acetonitrile analogue 79 was similar in potency to bis(4-fluorophenyl)methyl compound 1.The methylene analogue of 1 (78) and derivatives of 1 that contained a hydroxyl (76), carbamoyl (80), amino (81), or acetamido (82) substituent on the methyl group were less potent.In most cases substituents on the phenoxy ring, changes in the distance between the aryloxy group and the piperidine nitrogen, and the substitution of S, N(CH3), or CH2 for the oxygen atom of the aryloxy group had only a small to moderate effect on the potency.The best compounds in this series were more potent than verapamil, diltiazem, flunarizine, and lidoflazine, but were less potent than nifedipine.Compounds were evaluated for antihypertensive activity in spontaneusly hypertensive rats (SHR) at an oral dose of 30 mg/kg.Of the 55 compounds tested, only nine produced a statistically significant (p-1-piperidinyl>propoxy>-3-methoxyphenyl>ethanone (63), which produced a 35percent reduction in blood pressure and was similar in activity to nifedipine.At lower doses, however, 4--1-piperidine (93) was one of the most effective antihypertensive agents, producing reductions in blood pressure of 17 and 11percent at oral doses of 10 and 3 mg/kg, respectively; 63 was inactive at 10 mg/kg.

Aryl(alkyland alkylene)-N-((phenoxy and phenylthio)alkyl) aminoheterocyclics as cardiovascular, anthihistaminic, antisecretory and antiallergy agents

A method of treating cardiac dysfunction, the effects of histamine, and gastric secretion excesses with aryl(alkyl and alkylene)-N-[(phenoxy and phenythio)alkyl]aminoheterocyclics corresponding to the formula: STR1 wherein Ar is phenyl or substituted phenyl; R is phenyl, substituted phenyl, pyridinyl or cycloalkyl; A is hydrogen, hydroxy, cyano, amido and amino; Q is --CH2 --, --CH--, or --CHOH--; d and n are zero or one and the dotted lines form double bonds consistent with the valence of carbon; p is zero, one or two; m is one to six inclusive; B is oxygen, nitrogen, sulfur, sulfinyl or sulfonyl; z is zero or one; l is zero or one; W is hydrogen, loweralkyl, halo, nitro, loweralkoxy or hydroxy; X is hydrogen, loweralkyl, halogen, loweralkoxy or hydroxy; Y is --CH(OH)CH2 OH, --CH(OH)C(O)OH, --C(O)C(O)OH, --C(O)CH2 OH,--C(O)C(O)OCH3, --C(O)C(O)OC2 H5, --CH2 C(O)OC2 H5, --CH(OH)C(O)OCH3, --CH(OH)C(O)OC2 H5 or --C(O)CH2 OC(O)CH3 ; and the pharmaceutically acceptable salts thereof; in addition to the above methods of treatment, compounds wherein (B)z is oxygen are useful in a method of treating Gell and Coombs type 1 allergic responses in mammals.

Arylalkylheterocyclic amines,N-substituted by aryloxyalkyl group in a method for allergy treatment

A method of inhibiting Type 1 allergic responses in a living animal body with substituted heterocyclic amines is disclosed wherein the active agents are expressed generally by the formula which includes certain known and certain known compounds: STR1 wherein P is zero, one or two; m is one to six inclusive; A is selected from hydrogen, hydroxy or cyano; d is zero or one; Q is --CH--, CH2 -- or STR2 n is zero or one and when Q is --CH-- and n is one, a double bond is formed with one of the adjacent carbons but not both at the same time, and when n and d are zero at the same time, a double bond is formed between the α carbon and a carbon of the central heterocyclic amine ring; Ar, D and R are selected from phenyl, substituted phenyl, pyridinyl, thienyl, furanyl or naphthyl and in addition, R may have the values benzyl, substituted benzyl, cycloalkyl or loweralkyl and D may additionally have the values: 2H-1-benzopyran-2-one,4-oxo-4H-1-benzopyran-2-carboxylic acid loweralkyl ester, 2,3-dihydro-4H-1-benzopyran-4-one, 1,4-benzodioxanloweralkyl-2-yl or 1,1'-biphenyl-4-yl and the pharmaceutically acceptable salts thereof.